RxDoctor Payments DataLook up a doctor →

Richard Jeansonne, MD

Family Medicine · Mandeville, LANPI 1467468447

Payments from drug & device makers

$361,852in general payments, 2019–2025

Across 1,101 payments — averaging $328.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$257K
  • Novartis$55K
  • AbbVie$24K
  • Idorsia Pharmaceuticals US Inc$9K
  • Amgen$3K
  • AstraZeneca$2K
  • plus $12K from 48 others

What the payments were for

  • Speaking & faculty fees$28,94560%
  • Travel & lodging$1000%
  • Food & beverage$19,23440%
  • Education$2451%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$361,852 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$68,016
Medicare patients
209
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$104,794
MounjaroTirzepatide91$102,830
FarxigaDapagliflozin Propanediol37$34,531
JardianceEmpagliflozin34$30,281
Repatha SureclickEvolocumab40$22,836
ProliaDenosumab11$18,365
Soliqua 100-33Insulin Glargine/Lixisenatide17$17,881
OzempicSemaglutide14$13,296
TrulicityDulaglutide14$12,226
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$10,719
GemtesaVibegron17$8,308
MovantikNaloxegol Oxalate19$7,189
LinzessLinaclotide12$5,689
MyrbetriqMirabegron11$5,587
Clonidine42$4,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,754$115,055105 claims
PfizerEliquis$1,231$104,794154 claims
Boehringer IngelheimJardiance, Stiolto Respimat$752$41,00047 claims
AstraZenecaFarxiga, Symbicort$2,014$37,99153 claims
AmgenProlia$2,852$18,36511 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$243$17,88117 claims
Novo NordiskOzempic$612$13,29614 claims
AbbVieLinzess, Synthroid$24,258$8,51560 claims
Sumitomo Pharma America, Inc.Gemtesa$71$8,30817 claims
Astellas Pharma US IncMyrbetriq$668$5,58711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Mandeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →